文献速递心脑血管急症

低剂量甲氨蝶呤预防动脉粥样硬化事件

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
PubMed 文献 · N Engl J Med · 2018-11-10
一句话结论在既往心肌梗死或多支冠状动脉病变且合并2型糖尿病或代谢综合征的稳定动脉粥样硬化患者中,低剂量甲氨蝶呤未降低白细胞介素-1β、白细胞介素-6或C反应蛋白水平,也未比安慰剂减少心血管事件。

该随机双盲试验纳入4786例既往心肌梗死或多支冠状动脉病变且合并2型糖尿病或代谢综合征的患者,比较低剂量甲氨蝶呤(目标剂量15至20 mg每周)与匹配安慰剂,所有参与者每日接受1 mg叶酸。中位随访2.3年后试验停止,甲氨蝶呤组白细胞介素-1β、白细胞介素-6或C反应蛋白水平未低于安慰剂组。最终主要终点在甲氨蝶呤组201例、安慰剂组207例发生(发生率4.13 vs 4.31/100人年;风险比0.96;95%CI 0.79至1.16)。甲氨蝶呤与肝酶升高、白细胞计数和血细胞比容降低以及非基底细胞皮肤癌发生率高于安慰剂相关。

要点

  • 在既往心肌梗死或多支冠状动脉病变且合并2型糖尿病或代谢综合征的稳定动脉粥样硬化患者中,低剂量甲氨蝶呤(目标剂量15至20 mg每周)未比安慰剂减少心血管事件(最终主要终点风险比0.96;95%CI 0.79至1.16)。
  • 甲氨蝶呤未降低白细胞介素-1β、白细胞介素-6或C反应蛋白水平。
  • 甲氨蝶呤与肝酶升高、白细胞计数和血细胞比容降低以及非基底细胞皮肤癌发生率高于安慰剂相关。
  • 最终主要终点发生率:甲氨蝶呤组4.13/100人年 vs 安慰剂组4.31/100人年;原始主要终点发生率:甲氨蝶呤组3.46/100人年 vs 安慰剂组3.43/100人年(风险比1.01;95%CI 0.82至1.25)。

适用人群与场景

  • 既往心肌梗死或多支冠状动脉病变,且合并2型糖尿病或代谢综合征的稳定动脉粥样硬化患者。

处置流程与药物剂量

  • 低剂量甲氨蝶呤目标剂量15至20 mg每周,口服(原文未明确给药途径,但为口服药物常规;原文仅写目标剂量15至20 mg每周),所有参与者每日接受1 mg叶酸。

研究设计与关键结果

  • 随机双盲试验,纳入4786例患者,中位随访2.3年。
  • 最终主要终点(非致死性心肌梗死、非致死性卒中或心血管死亡,加因不稳定型心绞痛住院导致紧急血运重建)在甲氨蝶呤组201例、安慰剂组207例发生(发生率4.13 vs 4.31/100人年;风险比0.96;95%CI 0.79至1.16)。
  • 原始主要终点(非致死性心肌梗死、非致死性卒中或心血管死亡)在甲氨蝶呤组170例、安慰剂组167例发生(发生率3.46 vs 3.43/100人年;风险比1.01;95%CI 0.82至1.25)。
  • 甲氨蝶呤未降低白细胞介素-1β、白细胞介素-6或C反应蛋白水平。
  • 甲氨蝶呤与肝酶升高、白细胞计数和血细胞比容降低以及非基底细胞皮肤癌发生率高于安慰剂相关。

证据类型、等级与局限

  • 证据类型:随机双盲试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在稳定动脉粥样硬化患者中,低剂量甲氨蝶呤未减少心血管事件,不支持将其用于该人群的心血管事件预防。
  • 使用低剂量甲氨蝶呤时需监测肝酶、白细胞计数和血细胞比容,并注意非基底细胞皮肤癌风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit.

METHODS: We conducted a randomized, double-blind trial of low-dose methotrexate (at a target dose of 15 to 20 mg weekly) or matching placebo in 4786 patients with previous myocardial infarction or multivessel coronary disease who additionally had either type 2 diabetes or the metabolic syndrome. All participants received 1 mg of folate daily. The primary end point at the onset of the trial was a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Near the conclusion of the trial, but before unblinding, hospitalization for unstable angina that led to urgent revascularization was added to the primary end point.

RESULTS: The trial was stopped after a median follow-up of 2.3 years. Methotrexate did not result in lower interleukin-1β, interleukin-6, or C-reactive protein levels than placebo. The final primary end point occurred in 201 patients in the methotrexate group and in 207 in the placebo group (incidence rate, 4.13 vs. 4.31 per 100 person-years; hazard ratio, 0.96; 95% confidence interval [CI], 0.79 to 1.16). The original primary end point occurred in 170 patients in the methotrexate group and in 167 in the placebo group (incidence rate, 3.46 vs. 3.43 per 100 person-years; hazard ratio, 1.01; 95% CI, 0.82 to 1.25). Methotrexate was associated with elevations in liver-enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non-basal-cell skin cancers than placebo.

CONCLUSIONS: Among patients with stable atherosclerosis, low-dose methotrexate did not reduce levels of interleukin-1β, interleukin-6, or C-reactive protein and did not result in fewer cardiovascular events than placebo. (Funded by the National Heart, Lung, and Blood Institute; CIRT ClinicalTrials.gov number, NCT01594333.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2018. PMID: 30415610. doi:10.1056/NEJMoa1809798

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。